Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-8 long-term inclisiran extension in high cardiovascular risk with elevated LDL-C
2017-003092-55Phase 3Unknown
- Sponsor
- The Medicines Company
- Start
- Nov 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of inclisiran in hypercholesterolemia and cardiac morbidity, sponsored by The Medicines Company. Primary endpoint: Global lipid target attainment at end of study. Status: unknown.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemiacardiac morbidity
Beyond the preview
Go deeper on 2017-003092-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003092-55.